Intellia Therapeutics to Present at February Healthcare Investor Conferences
31 Janvier 2018 - 10:30PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on the development of curative therapeutics using
CRISPR/Cas9 technology, will present or host one-on-one meetings at
the following upcoming healthcare conferences in February:
Wednesday, February 14, 2018
Leerink Partners 7th Annual Healthcare
Conference
Who: Tom Barnes, Ph.D., Senior Vice President, Innovation
Sciences
Location: New York, New York
Presentation Time: 1:00pm EST
Tuesday, February 27, 2018
Credit Suisse 2018 Global Healthcare
Conference
Who: Tom Barnes, Ph.D., Senior Vice President, Innovation
Sciences
Location: London, United Kingdom
One-on-one meetings only
A live webcast of Intellia’s presentations will be accessible
through the Events and Presentations page of the Investor Relations
section of the company’s website at www.intelliatx.com. To access
the webcasts, please log on to the Intellia website approximately
15 minutes prior to the start time to ensure adequate time for any
software downloads that may be required. A replay of the webcast
will be available on Intellia’s website for 14 days following each
conference.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on the development of proprietary, curative therapeutics
using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9
technology has the potential to transform medicine by permanently
editing disease-associated genes in the human body with a single
treatment course. The combination of deep scientific, technical and
clinical development experience, along with its leading
intellectual property portfolio, puts Intellia in a unique position
to unlock broad therapeutic applications of the CRISPR/Cas9
technology and create a new class of therapeutic products. Learn
more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com;
Follow us on Twitter @intelliatweets
Investor
Contact: |
Media
Contact: |
Lindsey Trickett |
Jennifer Mound
Smoter |
Vice President,
Investor Relations
|
Senior Vice President,
External Affairs & |
+1 857-285-6211 |
Communications |
lindsey.trickett@intelliatx.com |
+1 857-706-1071 |
|
jenn.smoter@intelliatx.com |
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024